Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs)

as a standard target therapy in lung cancer

has been developed as a chemotherapy drug. Many clinical trials with EGFR-TKIs as third line

second line and first line treatment for lung cancer patients were carried out. Only EGFR gene mutations could predict benefit from EGFR-TKIs treatment for patients with lung cancer. Based on the experiences from the development of EGFR-TKIs

Crizotinib (Xalkori

Pfizer) is quickly approved for treatment in some patients with non-small cell lung carcinoma (NSCLC) harboring ALK gene rearrangement in every line. We believe that many other target drugs would be used in clinical practice to treat lung cancer patients. Identification of driver mutations in tumor specimens from Chinese patients is very important. Basic research and drug development in China will be promoted from the discovery of new driver mutations

especially in squamous cell lung cancer and small cell lung cancer. Based on the results of driver mutations tests

Chinese patients will be benefited from global research findings.